CRIS Current Research Information System

COSMI, BENILDE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.804
AS - Asia 7.498
EU - Europa 4.781
Continente sconosciuto - Info sul continente non disponibili 476
SA - Sud America 400
AF - Africa 338
OC - Oceania 55
Totale 22.352
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.618
SG - Singapore 2.439
CN - Cina 1.900
VN - Vietnam 1.383
GB - Regno Unito 1.254
IT - Italia 834
DE - Germania 674
HK - Hong Kong 508
SE - Svezia 372
FR - Francia 368
IN - India 364
RU - Federazione Russa 301
BR - Brasile 279
UA - Ucraina 214
BD - Bangladesh 206
IE - Irlanda 180
KR - Corea 178
NL - Olanda 166
JP - Giappone 141
ZA - Sudafrica 124
CA - Canada 97
EE - Estonia 92
FI - Finlandia 92
PH - Filippine 66
ID - Indonesia 62
SC - Seychelles 57
AR - Argentina 54
CI - Costa d'Avorio 54
MX - Messico 50
AT - Austria 39
AU - Australia 36
TH - Thailandia 34
EG - Egitto 30
TW - Taiwan 29
PL - Polonia 28
IQ - Iraq 27
BE - Belgio 26
CH - Svizzera 26
SA - Arabia Saudita 25
CZ - Repubblica Ceca 21
GR - Grecia 20
PK - Pakistan 19
ES - Italia 18
JO - Giordania 18
MY - Malesia 18
NZ - Nuova Zelanda 18
TR - Turchia 17
MA - Marocco 16
CO - Colombia 14
TG - Togo 14
UZ - Uzbekistan 14
CL - Cile 12
BG - Bulgaria 10
CR - Costa Rica 9
EC - Ecuador 9
PY - Paraguay 9
RO - Romania 9
DZ - Algeria 8
KE - Kenya 8
PE - Perù 8
JM - Giamaica 7
LB - Libano 7
TN - Tunisia 7
UY - Uruguay 7
AL - Albania 6
PS - Palestinian Territory 6
DK - Danimarca 5
HN - Honduras 5
HU - Ungheria 5
NG - Nigeria 5
VE - Venezuela 5
AZ - Azerbaigian 4
BH - Bahrain 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
HR - Croazia 4
IL - Israele 4
LT - Lituania 4
OM - Oman 4
AE - Emirati Arabi Uniti 3
GT - Guatemala 3
KZ - Kazakistan 3
MM - Myanmar 3
NP - Nepal 3
TT - Trinidad e Tobago 3
TZ - Tanzania 3
BO - Bolivia 2
GE - Georgia 2
KW - Kuwait 2
LK - Sri Lanka 2
LV - Lettonia 2
ML - Mali 2
NO - Norvegia 2
PA - Panama 2
PT - Portogallo 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BS - Bahamas 1
BZ - Belize 1
Totale 21.857
Salva come PNG Salva come JPEG
Città #
Singapore 1.700
Southend 1.055
Fairfield 942
Ashburn 741
Santa Clara 716
Hong Kong 478
Woodbridge 403
San Jose 401
Chandler 393
Seattle 390
Houston 383
Wilmington 382
Hefei 357
Cambridge 325
Ho Chi Minh City 320
Princeton 309
Dong Ket 267
Beijing 255
Hanoi 242
Boardman 211
Ann Arbor 206
Dublin 177
Lauterbourg 154
Seoul 154
Council Bluffs 135
Bologna 124
Jacksonville 124
Los Angeles 124
Nanjing 117
Tokyo 117
Westminster 114
Dallas 113
Padova 99
Berlin 93
New York 90
Buffalo 81
Helsinki 72
Jinan 70
San Diego 66
Shenyang 63
Turin 62
Redondo Beach 61
Abidjan 53
Milan 53
Saint Petersburg 52
Da Nang 45
São Paulo 43
Changsha 42
Munich 42
Chicago 41
Hebei 40
Dearborn 39
Frankfurt am Main 39
Redmond 37
Rome 36
Nanchang 34
The Dalles 34
Bengaluru 33
Guangzhou 31
Des Moines 30
San Francisco 30
Montreal 29
Haiphong 27
London 27
Shanghai 27
Brussels 26
Zhengzhou 26
Mülheim 25
Mexico City 24
Hangzhou 23
Can Tho 22
Johannesburg 22
Tianjin 22
Brooklyn 21
Jakarta 21
Falls Church 20
Moscow 20
Orem 20
Toronto 20
Vienna 20
Al Mansurah 19
Amman 18
Atlanta 18
Bühl 18
Jiaxing 18
Nuremberg 18
Phoenix 18
Warsaw 18
Norwalk 17
Olalla 17
Amsterdam 16
Baghdad 16
Bangkok 16
Bern 16
Denver 16
Fuzhou 16
Taiyuan 16
Biên Hòa 15
Mahé 15
Salt Lake City 15
Totale 14.218
Salva come PNG Salva come JPEG
Nome #
D-dimer in diagnosis and prevention of venous thrombosis: recent advances and their practical implications 590
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). 314
Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis 268
Thrombotic events after vaccination for covid-19 in Italy: a report from the Italian society on thrombosis and haemostasis registry 245
Padua Prediction Score and Hospital-Acquired Proximal and Isolated Distal Deep Vein Thrombosis in Symptomatic Patients 215
Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. 212
Diagnostic Accuracy of a New d -Dimer Assay (Sclavo Auto d -Dimer) for Exclusion of Deep Vein Thrombosis in Symptomatic Outpatients 211
Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. 199
Age and gender specific cut-off values to improve the performance of D: -dimer assays to predict the risk of venous thromboembolism recurrence. 194
Enhancing stroke risk prediction in patients with transient ischemic attack: insights from a prospective cohort study implementing fast-track care 192
D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis 192
Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. 192
D-Dimer testing for predictive recurrence risk in venous thromboembolism: looking for a useful threshold: reply to a rebuttal. 183
Thrombotic burden, D-dimer levels and complete compression ultrasound for diagnosis of acute symptomatic deep vein thrombosis of the lower limbs. 182
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE 181
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study 179
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study 174
Age‐adjusted D‐dimer, clinical pre‐test probability‐adjusted D‐dimer, and whole leg ultrasound in ruling out suspected proximal and calf deep venous thrombosis 172
Capsular Warning Syndrome: Features, Risk Profile, and Prognosis in a Large Prospective TIA Cohort 172
Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register 168
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 165
D-dimer, FVIII and thrombotic burden in the acute phase of deep vein thrombosis in relation to the risk of post-thrombotic syndrome 164
High plasma levels of factor VIII and risk of recurrence of venous thromboembolism 164
Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients 162
Incidence and clinical outcomes of heparin-induced thrombocytopenia: 11 year experience in a tertiary care university hospital 161
Review: recombinant factor VIIa does not differ from placebo for prevention or treatment of bleeding in patients without hemophilia 161
Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). 161
Diagnosis of deep vein thrombosis. 158
D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 158
D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. 158
Inherited and acquired thrombophilic alterations in patients with superficial vein thrombosis of lower limbs 157
Anticoagulant therapy for symptomatic calf deep vein thrombosis 155
External validation of the DASH prediction rule: a retrospective cohort study 155
Current management strategies and long-term clinical outcomes of upper extremity venous thrombosis 154
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations 154
D-dimer and reduced dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study. 153
Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. 152
Evaluation of a chemiluminescent immunoassay, the HemosIL AcuStar D-Dimer, in outpatients with clinically suspected deep venous thrombosis 150
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 150
Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans 150
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis. 147
Measurement of factor XIII (FXIII) activity by an automatic ammonia release assay using iodoacetamide blank-procedure: no more overestimation in the low activity range and better detection of severe FXIII deficiencies 147
Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH 147
D-dimer use for deep venous thrombosis exclusion in elderly patients: a comparative analysis of three different approaches to establish cut-off values for an assay with results expressed in D-dimer units 147
The incidence of heparin-induced thrombocytopenia in patients treated with low molecular weight heparin for superficial vein thrombosis 146
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: A prospective multicenter study 146
Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 145
Thrombin generation and intracranial atherosclerotic disease in patients with a transient ischaemic attack 145
Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication 145
Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. 144
Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. 143
Ultrasound Characteristics of Calf Deep Vein Thrombosis and Residual Vein Obstruction After Low Molecular Weight Heparin Treatment 143
D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the Prolong extension study. 143
Predicting the risk of recurrence of venous thromboembolism. 141
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms 141
Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia 141
The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies. 140
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. 140
D-dimer and risk of venous thromboembolism recurrence: Comparison of two studies with similar designs but different laboratory and clinical results 139
Malattia tromboembolica polmonare 139
Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. 138
Gynecological Cancer and Venous Thromboembolism: A Narrative Review to Increase Awareness and Improve Risk Assessment and Prevention 137
An update on the pharmaceutical management of thrombosis 137
The influence of VKORC1 3730 G > A polymorphism on warfarin dose: reply. 135
Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 135
Is there a role for intervention radiology for the treatment of lower limb deep vein thrombosis in the era of direct oral anticoagulants? A comprehensive review 135
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. 132
Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. 132
ACP Journal Club. Review: Low-molecular-weight heparin reduces risk for venous thromboembolism in adults with leg immobilization. 131
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants 131
Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. 131
Inappropriate Underdosing of Direct Oral Anticoagulants in Atrial Fibrillation Patients: Results from the START2-AF Registry 130
D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 129
Relevance of immobility as a risk factor for symptomatic proximal and isolated distal deep vein thrombosis in acutely ill medical inpatients 129
Extended treatment for venous thromboembolism: how long is long enough? 128
D-dimer, oral anticoagulation, and venous thromboembolism recurrence 128
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. 128
Is there a role for oral anticoagulant therapy in patients with peripheral arterial disease? 128
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of a portable prothrombin time monitor (COAGUCHECK) 128
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. 126
The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis 125
ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. 124
The Post-thrombotic Syndrome-Prevention and Treatment: VAS-European Independent Foundation in Angiology/Vascular Medicine Position Paper 123
The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study). 123
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. 123
Risks factors for highly unstable response to oral anticoagulation: a case-control study. 123
Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis 123
Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therap 123
Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor. 121
Whole-Arm Ultrasound for Suspected Upper-Extremity Deep Venous Thrombosis in Outpatients Reply 121
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 120
D-dimer testing to determine the duration of anticoagulation therapy. 120
Heparin-induced thrombocytopenia: new insights into the immune response 120
Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. 119
Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register 119
Value of D-dimer testing to decide duration of anticoagulation after deep vein thrombosis: yes. 118
DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register 118
Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia 118
Current management of heparin-induced thrombocytopenia 117
Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art. 115
Totale 15.487
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.832
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.832
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.846 0 95 177 116 246 111 63 207 87 97 289 358
2022/20232.016 261 281 117 275 111 162 59 116 283 93 172 86
2023/2024427 36 97 44 30 28 20 20 34 17 41 27 33
2024/20253.600 82 533 166 225 943 173 245 48 106 234 173 672
2025/20267.720 519 753 777 547 1.061 484 696 267 1.191 591 442 392
2026/2027653 461 192 0 0 0 0 0 0 0 0 0 0
Totale 22.352